Abevmy IV Infusion 100 mg/4 ml contains Bevacizumab, a recombinant humanized monoclonal antibody that plays a vital role in targeted cancer therapy. It works by inhibiting vascular endothelial growth factor (VEGF), a key protein responsible for the formation of new blood vessels (angiogenesis) that supply tumors with oxygen and nutrients. By blocking VEGF, Bevacizumab helps slow tumor growth and spread.

Abevmy is widely used in the management of several solid tumors and is administered intravenously under the supervision of experienced healthcare professionals. It is typically used either alone or in combination with chemotherapy or other anticancer agents, depending on the type and stage of cancer.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Targeted anticancer therapy
Anti-angiogenic agent

Indications

Abevmy IV Infusion is indicated for the treatment of various malignancies, including:

• Metastatic colorectal cancer

• Non-small cell lung cancer (non-squamous type)

• Recurrent or metastatic cervical cancer

• Epithelial ovarian, fallopian tube, or primary peritoneal cancer

• Renal cell carcinoma

• Glioblastoma (in certain clinical settings)

Pharmacology

Bevacizumab selectively binds to VEGF-A, preventing it from interacting with its receptors (VEGFR-1 and VEGFR-2) on endothelial cells. This inhibition reduces the formation of new blood vessels within tumors, leading to decreased tumor blood supply, inhibition of tumor growth, and potential tumor regression. Its targeted mechanism allows it to complement conventional chemotherapy by enhancing therapeutic outcomes.

Dosage and Administration

• Administered as an intravenous infusion.

• Dosage and infusion schedule depend on the specific cancer type, patient body weight, and treatment regimen.

• Must be diluted and given by trained healthcare professionals in a clinical setting.

• Patients should be monitored during and after infusion for infusion-related reactions.

Precautions and Warnings

• Not recommended during pregnancy due to risk of fetal harm.

• Use with caution in patients with hypertension, bleeding disorders, recent surgery, or impaired wound healing.

• Blood pressure and urine protein levels should be regularly monitored.

• Increased risk of bleeding, gastrointestinal perforation, and thromboembolic events may occur.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Hypertension

• Fatigue

• Nausea and vomiting

• Diarrhea

• Proteinuria

• Headache

Serious adverse effects, although less common, should be promptly evaluated by a healthcare professional.

Storage

• Store at 2°C to 8°C (refrigerated).

• Do not freeze.

• Protect from light.

• Keep out of reach of children.

Pack Size

100 mg Bevacizumab in 4 ml vial for intravenous infusion.